Systemic sclerosis associated myopathy: how to treat

Area of Science:

• Rheumatology
• Immunology
• Internal Medicine

Background:

• Systemic sclerosis (SSc) and myositis can co-occur as an overlap syndrome.
• Immunological biomarkers, including anti-PM/Scl and anti-Ku antibodies, are crucial for diagnosing this syndrome.
• Understanding the distinct manifestations is key for effective management.

Purpose of the Study:

• To review the treatment strategies for characteristic manifestations of the SSc-myositis overlap syndrome.
• To highlight the importance of identifying specific myositis phenotypes in SSc patients.
• To discuss the role of autoantibodies and vasculopathy in this condition.

Main Methods:

• Literature review focusing on SSc-myositis overlap syndrome.
• Analysis of treatment approaches for various clinical phenotypes.
• Discussion of diagnostic biomarkers and underlying mechanisms.

Main Results:

• Early identification of fibrotic SSc and sporadic inclusion body myositis is crucial to avoid ineffective immunosuppression.
• Dermatomyositis, non-specific myositis, and immune-mediated necrotizing myopathy require conventional immunosuppressive therapy.
• High-dose glucocorticoids can precipitate scleroderma renal crisis in SSc patients.
• The "double trouble" of hereditary myopathy with autoimmune phenomena necessitates awareness.
• Specific autoantibodies (anti-PM/Scl, anti-Ku) aid in defining phenotypes and guiding therapy.
• Vasculopathy is a key linking mechanism between SSc and myositis.

Conclusions:

• Treatment for SSc-associated myopathy must be individualized based on the specific organs affected.
• Accurate identification of clinical, pathological, and immunological phenotypes is essential for optimal therapeutic decisions.